计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| C125447-10mg |
10mg |
现货 ![]() |
| |
| C125447-50mg |
50mg |
现货 ![]() |
| |
| C125447-250mg |
250mg |
期货 ![]() |
|
| 别名 | 卡奈替尼 | 卡耐替尼 |
|---|---|
| 英文别名 | PD-183805 | EC-000.2258 | BDBM4779 | N-(4-(3-chloro-4-fluorophenylamino)-7-(3-morpholinopropoxy)quinazolin-6-yl)acrylamide | AC-28654 | Canertinib [INN] | NCGC00182713-18 | GTPL5675 | Canertinib - CI-1033 | HMS3244N17 | N-[4-(3-chloro-4-fluoro-anilino)-7- |
| 规格或纯度 | Moligand™, ≥98% |
| 英文名称 | Canertinib (CI-1033) |
| 生化机理 | 卡尼替尼是表皮生长因子受体酪氨酸残基磷酸化的强效选择性抑制剂,可阻断信号传递并阻止血管生成。卡纳替尼的 IC50 值为 1.5nM。此外,卡纳替尼抑制表皮生长因子受体的作用还能以可滴定的方式增加癌细胞株的凋亡。 |
| 储存温度 | -20°C储存 |
| 运输条件 | 超低温冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 表皮生长因子受体抑制剂;erb-b2 受体酪氨酸激酶 2 抑制剂 |
| 产品介绍 |
Canertinib (CI-1033)是一种pan-ErbB抑制剂,同时抑制EGFR和ErbB2,IC50分别为1.5 nM和9.0 nM,但对PDGFR, FGFR, InsR, PKC,和CDK1/2/4等均无抑制活性。An irreversible pan-erbB tyrosine kinase inhibitor. Canertinib (CI-1033) is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM, no activity to PDGFR, FGFR, InsR, PKC, or CDK1/2/4. |
| 纯度 | ≥98% |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide |
| INCHI | 1S/C24H25ClFN5O3/c1-2-23(32)30-21-13-17-20(14-22(21)34-9-3-6-31-7-10-33-11-8-31)27-15-28-24(17)29-16-4-5-19(26)18(25)12-16/h2,4-5,12-15H,1,3,6-11H2,(H,30,32)(H,27,28,29) |
| InChi Key | OMZCMEYTWSXEPZ-UHFFFAOYSA-N |
| Smiles | C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 |
| Isomeric SMILES | C=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4 |
| 分子量 | 485.94 |
| Reaxy-Rn | 8659240 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=8659240&ln= |
| 溶解性 | Soluble in DMSO (2 mg/ml), methanol, ethanol (9 mg/ml), and water (<1 mg/ml). |
|---|---|
| 分子量 | 485.900 g/mol |
| XLogP3 | 3.900 |
| 氢键供体数Hydrogen Bond Donor Count | 2 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 9 |
| 精确质量Exact Mass | 485.163 Da |
| 单同位素质量Monoisotopic Mass | 485.163 Da |
| 拓扑极表面积Topological Polar Surface Area | 88.600 Ų |
| 重原子数Heavy Atom Count | 34 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 671.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 0 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Smaill JB, Rewcastle GW, Loo JA, Greis KD, Chan OH, Reyner EL, Lipka E, Showalter HD, Vincent PW, Elliott WL et al.. (2000) Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.. J Med Chem, 43 (7): (1380-97). [PMID:10753475] |
| 2. Rao GS, Murray S, Ethier SP. (2000) Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor.. Int J Radiat Oncol Biol Phys, 48 (5): (1519-28). [PMID:11121658] |
| 3. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW. (2002) Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.. Semin Oncol, 29 (3 Suppl 11): (11-21). [PMID:12138393] |
| 4. Rixe O, Franco SX, Yardley DA, Johnston SR, Martin M, Arun BK, Letrent SP, Rugo HS. (2009) A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer.. Cancer Chemother Pharmacol, 64 (6): (1139-48). [PMID:19294387] |
| 5. Trinks C, Severinsson EA, Holmlund B, Gréen A, Gréen H, Jönsson JI, Hallbeck AL, Walz TM. (2011) The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.. Biochem Biophys Res Commun, 410 (3): (422-7). [PMID:21669187] |
| 6. Nordigården A, Zetterblad J, Trinks C, Gréen H, Eliasson P, Druid P, Lotfi K, Rönnstrand L, Walz TM, Jönsson JI. (2011) Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.. Br J Haematol, 155 (2): (198-208). [PMID:21848891] |